April 2017 in “The Journal of urology/The journal of urology” 5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
October 2006 in “Clinical Cancer Research” Antioxidants can block the cancer-fighting effects of doxorubicin.
1 citations
,
November 2014 in “Thérapie” Potassium channel activators like nicotinamide and minoxidil might help treat solid tumors.
20 citations
,
August 2010 in “The Journal of Urology” Ezetimibe effectively reduces prostate size in cases of benign prostatic hyperplasia.
24 citations
,
September 2002 in “Der Urologe” A stronger dual 5α-reductase inhibitor could improve treatment for benign prostatic hyperplasia by further reducing DHT levels.
October 2008 in “Journal of Intellectual Property Law & Practice” The article concludes that recent legal rulings have strengthened the protection of pharmaceutical patents against generic competition.
4 citations
,
April 2025 in “Scientific Reports” Platelet-rich plasma can temporarily inhibit some drug-resistant bacteria in diabetic foot infections.
Testosterone undecanoate can reduce the negative effects of Finasteride on male reproductive health.
April 2011 in “Cancer Research” 20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.
6 citations
,
June 2009 in “Journal of Clinical Oncology” 5-α-reductase inhibitors don't prevent prostate cancer but may reduce unnecessary biopsies.